Wang Jin, Liu Sha, Sun Guo Ping, Wang Fang, Zou Yan Feng, Jiao Yang, Ning Jie, Xu Jing
Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui - China.
Int J Biol Markers. 2014 Jun 25;29(2):e129-41. doi: 10.5301/jbm.5000058.
The prognostic significance of the expression of the miR-221/222 family in cancer remains controversial. We here performed a meta-analysis of published data investigating the effects of miR-221/222 expression on both overall survival (OS) and disease-free survival (DFS) among patients with cancer.
A systematic search of the PubMed, Embase, Cochrane, and CNKI databases was performed with the last search being updated on March 15, 2013. The hazard ratio (HR) and its 95% confidence interval (95% CI) were used to assess the strength of association.
A total of 17 studies involving 1,204 subjects were included in this meta-analysis. When assessing the prognostic significance of miR-221 expression, the pooled HR was 1.91 (95% CI: 1.28-2.85, p=0.002) for OS and 1.36 (95% CI: 0.88-2.09, p=0.163) for DFS. When assessing the prognostic significance of miR-222 expression, the pooled HR was 2.15 (95% CI: 1.51-3.06, p<0.0001) for OS and 1.37 (95% CI: 0.45-4.13, p=0.581) for DFS. We also found that an elevated miR-221 expression was significantly associated with poor OS when stratifying by ethnicity, cancer type, statistical methodology, sample, and quality assessment. There was no evidence of publication bias.
The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors.
miR - 221/222家族在癌症中的表达的预后意义仍存在争议。我们在此对已发表的数据进行荟萃分析，以研究miR - 221/222表达对癌症患者总生存期（OS）和无病生存期（DFS）的影响。
对PubMed、Embase、Cochrane和中国知网数据库进行系统检索，最后一次检索于2013年3月15日更新。采用风险比（HR）及其95%置信区间（95%CI）来评估关联强度。
本荟萃分析共纳入17项研究，涉及1204名受试者。在评估miR - 221表达的预后意义时，OS的合并HR为1.91（95%CI：1.28 - 2.85，p = 0.002），DFS的合并HR为1.36（95%CI：0.88 - 2.09，p = 0.163）。在评估miR - 222表达的预后意义时，OS的合并HR为2.15（95%CI：1.51 - 3.06，p < 0.0001），DFS的合并HR为1.37（95%CI：0.45 - 4.13，p = 0.581）。我们还发现，按种族、癌症类型、统计方法、样本和质量评估分层时，miR - 221表达升高与较差的OS显著相关。没有发表偏倚的证据。
荟萃分析表明，miR - 221和miR - 222表达升高与癌症患者较差的OS相关。miR - 221/222簇可能在临床实践中用作潜在的治疗策略。需要更多工作来充分阐明miR - 221/222家族在人类肿瘤中的作用。
